The BSI-CIPN Clinical Guidelines Special Interest Group is working to develop a clinical guideline on Good Syndrome, for which plans were presented at the BSI-CIPN Conference 2024.
Good Syndrome is a clinically important and often poorly diagnosed condition characterised by the combination of thymoma and a humoral or combined immune deficiency. It is estimated that approximately 15% of patients with thymoma have Good Syndrome. Undiagnosed, patients have a risk of serious and life-threatening infection, including opportunistic infections.
Currently, no consensus guidelines exist for diagnosis and definitions vary in published literature. There are also no universally accepted recommendations on screening, work-up or management.
We are currently convening the Writing Group for this guideline, chaired by Dr David Lowe, Consultant Clinical Immunologist, Royal Free London NHS FT, and we would like to invite expressions of interest from members of the BSI-CIPN to join the Writing Group. We will also be approaching professional organisations from other relevant specialties and patient organisations to invite their input.
The time commitment will be variable, but will not constitute more than one meeting every two weeks, plus drafting time, with a target deadline of a first draft of the guidance by December 2025.
We encourage trainees to submit expressions of interest to join the writing group, and will have mechanisms in place to ensure that trainees are supported during their time in the group.
If you are interested in joining the Good Syndrome Writing Group, please email cipn@immunology.org with a short expression of interest statement.
The deadline for applications is Monday 18 August 2025.
Read our data protection policy to find out what we're doing to keep your information safe.